Journal of Thrombosis and Thrombolysis

, Volume 35, Issue 3, pp 312–319 | Cite as

Assessing bleeding risk in patients taking anticoagulants

CME/CNE Article

Abstract

Anticoagulant medications are commonly used for the prevention and treatment of thromboembolism. Although highly effective, they are also associated with significant bleeding risks. Numerous individual clinical factors have been linked to an increased risk of hemorrhage, including older age, anemia, and renal disease. To help quantify hemorrhage risk for individual patients, a number of clinical risk prediction tools have been developed. These risk prediction tools differ in how they were derived and how they identify and weight individual risk factors. At present, their ability to effective predict anticoagulant-associated hemorrhage remains modest. Use of risk prediction tools to estimate bleeding in clinical practice is most influential when applied to patients at the lower spectrum of thromboembolic risk, when the risk of hemorrhage will more strongly affect clinical decisions about anticoagulation. Using risk tools may also help counsel and inform patients about their potential risk for hemorrhage while on anticoagulants, and can identify patients who might benefit from more careful management of anticoagulation.

Keywords

Anticoagulation Hemorrhage Risk stratification Warfarin 

References

  1. 1.
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:160S–198SPubMedCrossRefGoogle Scholar
  2. 2.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956PubMedCrossRefGoogle Scholar
  3. 3.
    Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRefGoogle Scholar
  4. 4.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRefGoogle Scholar
  5. 5.
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352PubMedCrossRefGoogle Scholar
  6. 6.
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815PubMedCrossRefGoogle Scholar
  7. 7.
    Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147:590–592PubMedGoogle Scholar
  8. 8.
    Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:257S–298SPubMedCrossRefGoogle Scholar
  9. 9.
    Linkins L-A, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139:893–900PubMedGoogle Scholar
  10. 10.
    Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG et al (2007) Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120:700–705PubMedCrossRefGoogle Scholar
  11. 11.
    Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al (2012) Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 43:1795–1799PubMedCrossRefGoogle Scholar
  12. 12.
    Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745–752PubMedGoogle Scholar
  13. 13.
    Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S–e494SPubMedCrossRefGoogle Scholar
  14. 14.
    Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91–99PubMedCrossRefGoogle Scholar
  15. 15.
    Hart RG, Tonarelli SB, Pearce LA (2005) Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 36:1588–1593PubMedCrossRefGoogle Scholar
  16. 16.
    Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D’Angelo A et al (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805–810PubMedGoogle Scholar
  17. 17.
    Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J et al (2012) Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 125:773–778PubMedCrossRefGoogle Scholar
  18. 18.
    Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW (2005) Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 118:612–617PubMedCrossRefGoogle Scholar
  19. 19.
    Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159:677–685PubMedCrossRefGoogle Scholar
  20. 20.
    Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V (2006) The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 95:782–787PubMedGoogle Scholar
  21. 21.
    Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF (2004) Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 35:2362–2367PubMedCrossRefGoogle Scholar
  22. 22.
    White HD, Gruber M, Feyzi J, Kaatz S, Tse H-F, Husted S et al (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239–245PubMedCrossRefGoogle Scholar
  23. 23.
    Adam SS, McDuffie JR, Ortel TL, Williams JW Jr (2012) Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. doi:10.7326/0003-4819-157-10-201211200-00532 PubMedGoogle Scholar
  24. 24.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–2372PubMedCrossRefGoogle Scholar
  25. 25.
    Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144–152PubMedCrossRefGoogle Scholar
  26. 26.
    Kuijer PM, Hutten BA, Prins MH, Büller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457–460PubMedCrossRefGoogle Scholar
  27. 27.
    Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130:1390–1396PubMedCrossRefGoogle Scholar
  28. 28.
    Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713–719PubMedCrossRefGoogle Scholar
  29. 29.
    Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26–31PubMedGoogle Scholar
  30. 30.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100PubMedCrossRefGoogle Scholar
  31. 31.
    Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al (2011) A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58:395–401PubMedCrossRefGoogle Scholar
  32. 32.
    Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639PubMedCrossRefGoogle Scholar
  33. 33.
    Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH (2012) Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atria. J Am Coll Cardiol 60:861–867PubMedCrossRefGoogle Scholar
  34. 34.
    Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V et al (2012) Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 5:312–318PubMedCrossRefGoogle Scholar
  35. 35.
    Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M et al (2012) Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real world” anticoagulated atrial fibrillation population. Chest. doi:10.1378/chest.12-0608 Google Scholar
  36. 36.
    Scherz N, Méan M, Limacher A, Righini M, Jaeger K, Beer H-J et al (2012) Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost. doi:10.1111/jth.12111 Google Scholar
  37. 37.
    Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D (2012) Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 125:1095–1102PubMedCrossRefGoogle Scholar
  38. 38.
    Friberg L, Rosenqvist M, Lip GYH (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33:1500–1510PubMedCrossRefGoogle Scholar
  39. 39.
    Olesen JB, Lip GYH, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C et al (2011) Bleeding risk in “real world” patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 9:1460–1467PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Hospital MedicineUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations